Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + binimetinib before local treatment for BRAF-mutated melanoma brain metastases (Phase II)
2018-002530-20Phase 2Active
- Sponsor
- Gem
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of encorafenib and binimetinib in melanoma (2 cohorts), sponsored by Gem. Primary endpoints: Intracranial objective response rate (ORR) by RECIST 1.1 before local treatment in cohort 1 and Intracranial objective response rate (ORR) by RECIST 1.1 before local treatment in cohort 2. Started Mar 2019; status: active.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-002530-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002530-20.